Last reviewed · How we verify
NCT04052048
Active Surveillance SNEP Assay Registry Trial for Prostate Cancer
trial testing Subtraction Normalized Expression of Phagocytes Blood Test in Prostate Cancer Aggressiveness in 2,000 participants. Currently enrolling.
15 November 2026
Quick facts
| Lead sponsor | Immunis.AI |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 9 September 2019 |
| Primary completion | 15 November 2026 |
| Estimated completion | 30 September 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Subtraction Normalized Expression of Phagocytes Blood Test
Conditions studied
- Prostate Cancer Aggressiveness — all drugs for Prostate Cancer Aggressiveness →
Sponsor
Immunis.AI
Who can join
Adults 40 to 80, male only, with Prostate Cancer Aggressiveness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A multi-center, prospective active surveillance registry trial assessing the performance of a non-invasive blood test for indolent prostate cancer disease management.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04052048
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer Aggressiveness
Currently open trials in the same condition.
- NCT03263650 — Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC · Phase 2 · active not recruiting
Other Immunis.AI trials
Trials by the same sponsor.
- NCT05370300 — SNAPS Breast Cancer Patient Study Breast Cancer Patients · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04052048 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Immunis.AI
- Last refreshed: 2 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04052048.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing